Document:

Exhibit 10.14

 

EXECUTIVE EMPLOYMENT AGREEMENT

 

This Executive Employment
Agreement (“Agreement”) is made and entered into by Humacyte, Inc. (“Humacyte” or the “Company”)
and Jeffrey Lawson, M.D. (hereinafter “Executive”) effective June 19, 2018.

 

WHEREAS, Executive has served
as Humacyte’s Chief Medical Officer; and

 

WHEREAS, the Company now desires
to employ Executive as its President and Chief Executive Officer and Executive desires to accept such employment on the terms set
forth below.

 

NOW THEREFORE, in consideration
of the mutual promises set forth below and other good and valuable consideration, the receipt and sufficiency of which the parties
acknowledge, the Company and Executive agree as follows:

 

1. NATURE OF EMPLOYMENT
AND DUTIES. Executive shall serve as Company’s President and Chief Executive Officer, effective on the date first
written above (the “Effective Date”) and have such responsibilities and authority as the Company may lawfully assign
from time to time. Additionally, Executive agrees to perform such other duties consistent with those of an executive at his level
as the Company may lawfully direct from time to time. Executive shall report to the Company’s Board of Directors and, upon
appointment by the Company’s shareholders, shall serve as a member, ex officio, of the Company’s Board of Directors.

 

1.1 Executive shall perform
all duties and exercise all authority in accordance with, and otherwise comply with, all lawful Company policies, procedures, practices
and directions.

 

1.2 Executive shall devote all
of his working time, reasonable best efforts, knowledge and experience to perform his duties and advance the Company’s interests.
During his employment, Executive shall not, directly or through others, engage in, assist or consult with any other business or
business activities of any nature whatsoever (including board memberships) without the Company’s prior written consent; provided,
however, this provision does not prohibit him from personally owning and trading in stocks, bonds, securities, real estate, commodities
or other investment properties for his own benefit which do not create actual or potential conflicts of interest with the Company;
nor does it prohibit him from serving on advisory boards, so long as such service does not violate his obligations under the Non-Competition
Agreement, as defined herein, or distract him from his duties under this Agreement. Notwithstanding the foregoing, Executive shall
continue to be permitted to serve as the President-Elect, President and Past President of the Vascular Access Society of the Americas
(“VASA”) and on the Executive Advisory Board of the NIH Department of Defense funded Traumatic Injury study (“TACTIC”).

 

1.3 Humacyte acknowledges that
Executive holds shares in InnAVasc Medical, Inc. (“InnAVasc”). Executive may continue to hold and vote those InnAVasc
shares and may transfer them in whole or in part. Executive acknowledges, however, that any different role or relationship he may
have with InnAVasc could create an actual or potential conflict of interest with Humacyte. While employed as Humacyte’s President
and/or CEO, Executive may act with respect to InnAVasc solely as a passive shareholder. While employed as Humacyte’s President
and/or CEO, Executive shall not, directly or through others, without the express written permission of the Board of Directors,
engage in any InnAVasc business or InnAVasc business activity of any nature whatsoever, whether paid or unpaid, including but not
limited to: (a) hold any board membership in InnAVasc or its affiliates; (b) participate in any way in any medical trials
or demonstrations of any products of InnAVasc or its affiliates; (c) manage, supervise, advise, assist, or act as a consultant
to, InnAVasc or its affiliates in any way; or, (d) purport to represent InnAVasc or its affiliates in any way.

 

    	 

    	

    

 

2. COMPENSATION.

 

2.1 Base Salary. Executive’s
annual base salary for all services rendered shall be Five Hundred Fifty Thousand and No/100 Dollars ($550,000.00) (less applicable
taxes and withholdings), payable in accordance with the Company’s policies, procedures and practices as they may exist from
time to time. Executive’s base salary shall be reviewed by the Company’s Board of Directors in accordance with the
Company’s policies, procedures, and practices as they may exist from time to time. Executive’s base salary shall not
be reduced except in connection with an across the board reduction of all similarly situated executives in an amount not to exceed
ten percent (10%) of the Executive’s then current base salary.

 

2.2 Benefits. Executive
may participate in all medical, dental and disability insurance, Simple IRA, 401(k), profit sharing, pension, personal leave, and
other employee benefit plans and programs that may be made available from time to time to senior employees of the Company provided,
however, that Executive’s participation in any such benefit plans and programs is subject to the applicable terms, conditions
and eligibility requirements of these plans and programs, some of which are within the plan administrator’s discretion, as
they may exist from time to time. Notwithstanding anything to the contrary in the foregoing, Executive shall be entitled to four
(4) weeks of vacation each year.

 

2.3 Business Expenses.
Executive shall be reimbursed for reasonable expenses actually incurred by him in performing services under this Agreement in accordance
with and subject to the terms and conditions of the applicable Company reimbursement policies, procedures and practices as they
may exist from time to time.

 

2.4 Annual Incentive Bonus.
Executive shall be eligible for consideration for an annual incentive bonus of up to fifty percent (50%) of Executive’s then
current base salary in accordance with objectives to be determined between the Company and Executive within ninety (90) days of
the Effective Date for fiscal year 2018 and on or before January 15 of each succeeding year. Any bonus shall be awarded in the
Board’s sole discretion taking into consideration Executive’s achievement of the agreed upon objectives. Except as
expressly provided otherwise herein, by Company policy, or by the terms of any annual bonus plan, Executive must be employed on
the date any such annual incentive bonus is paid in order to receive such bonus and the bonus is not earned unless the Executive
is employed on that date; however, if Executive’s employment is terminated by the Company without Cause or by the Executive
for Good Reason before the payment date, then Executive shall earn any bonus awarded for the prior fiscal year that had not been
paid prior to such termination and a pro rata portion of the bonus that the Board awards for the current fiscal year, with the
pro rata portion calculated based on the number of days that Executive was employed during the relevant fiscal year prior to termination.

 

    	2

    	

    

 

2.5 Stock Option Grant.
Executive will be eligible to participate in the Company’s 2015 Omnibus Incentive Plan (as amended from time to time, the
“Plan”) in accordance with the terms and conditions of the Plan. The Company shall award him an initial stock option
grant of 4,550,000 shares (the “Option Shares”) (in addition to the option grants awarded to Executive prior to this
Agreement). Subject to Executive’s Stock Option Agreement, one-third of the 4,550,000 shares will vest on each of the three
anniversaries after the Effective Date. All grants under the Plan, and the terms of all such grants, are subject to and must be
approved by the Board, and the stock option grant referenced above remains subject to the Board’s review and approval. If
approved, Executive will be required to execute the Company’s standard Stock Option Agreement as a prerequisite to participation
in the Plan. The Option Shares shall fully vest upon a Corporate Transaction (as defined in the Plan).

 

2.6 Modifications. Nothing
in this Agreement shall require the Company to create, continue or refrain from amending, modifying, revising or revoking any of
the plans, programs or benefits described in Sections 2.2, 2.3, 2.4 and 2.5. Any amendments, modifications, revisions and revocations
of these plans, programs and benefits shall apply to Executive.

 

3. TERMINATION OF EMPLOYMENT.
Executive’s employment shall continue from the Effective Date until terminated as provided herein.

 

3.1 Termination Without Cause.
Either party may terminate this Agreement and the employment relationship hereunder without cause at any time upon giving the other
party thirty (30) days’ prior written notice.

 

3.2 Termination by the Company
for Cause. The Company may terminate this Agreement and Executive’s employment hereunder immediately without notice at
any time for the following reasons which shall constitute “Cause” for purposes of this Agreement:

 

(a) Executive’s death;

 

(b) Executive’s physical
or mental disability that prevents him from performing the essential functions of his duties satisfactorily for a period of one
hundred eighty (180) consecutive days or one hundred eighty (180) days in total within any 365 consecutive-day period as determined
by the Company in its reasonable discretion and in accordance with applicable law;

 

(c) any act or omission of Executive
constituting knowing and willful misconduct (including knowing and willful violation of material Company’s policies);

 

(d) gross negligence;

 

(e) fraud, misappropriation,
embezzlement;

 

(f) conviction of a non-traffic
related felony;

 

    3

     

    

 

(g) violation of the Company’s
conflict of interest policy or engaging in competitive business activities in violation of this Agreement; or

 

(h) Executive’s material
breach of this Agreement or breach of the Non-Competition Agreement.

 

Provided however, prior to a termination for Cause
based on Sections 3.2 (c), (d), (g), or (h), the Company shall provide Executive with written notice of the alleged basis for termination
and a thirty (30) day opportunity to cure. For the avoidance of doubt, “Cause” shall not exist under Sections 3.2 (c),
(d), (g), or (h) if Executive cures the alleged basis for termination within the thirty (30) day cure period.

 

3.3 Termination by Executive
for Good Reason. Executive may terminate this Agreement and Executive’s employment hereunder for the following reasons
which shall constitute “Good Reason” for purposes of this Agreement: (a) the Company’s material breach of this
Agreement; or (b) a material adverse change, by the Company without Executive’s consent, in or to Executive’s salary,
expense reimbursement rights, bonus eligibility, authority or responsibilities, provided that Executive may only terminate for
Good Reason if he provides the Company with written notice of the existence of the condition giving rise to Good Reason within
thirty (30) days of its initial existence, the Company has not cured the condition within thirty (30) days of the notice, and if
the Company fails to cure the condition within such cure period, Executive terminates employment within seven (7) days after the
end of the cure period.

 

3.4 Survival. This Agreement
shall terminate upon the termination of the employment relationship established hereunder with the following exceptions: Section
4 (Compensation and Benefits Upon Termination), Section 5 (Non-Competition) and Section 13 (Section 409A) shall survive the termination
of Executive’s employment and/or the expiration or termination of this Agreement, regardless of the reasons for such expiration
or termination.

 

4. COMPENSATION AND
BENEFITS UPON TERMINATION.

 

4.1 The Company’s obligation
to compensate Executive ceases on the effective termination date except as to: (a) amounts due or earned at that time; and (b)
any compensation and/or benefits which he may be entitled to receive pursuant to Section 4.2.

 

4.2 If the Company terminates
Executive’s employment pursuant to Section 3.1 (without Cause) or if Executive terminates Executive’s employment pursuant
to Section 3.3 (Good Reason), then the Company’s sole obligations shall be to pay Executive:

 

(a) amounts due on the effective
termination date; and

 

(b) an amount equal to twelve
(12) months of Executive’s then current base salary (less any applicable taxes and withholdings) with payment of such amount
to be made in substantially equal installments on the same payroll schedule applicable to Executive immediately prior to his separation
from service. Such payments shall commence on the first such payroll date following the sixtieth (60th) day following
his separation from service provided that he has returned by such sixtieth (60th) day an executed, customary Release
of all claims provided by the Company and any revocation period in the Release has expired. In addition, the Company shall pay
Executive any accrued, earned and unpaid bonus pursuant to Section 2.4. The Company will also reimburse the Executive for the cost
to continue Executive’s and his family’s health insurance under COBRA for a period of twelve (12) months.

 

    	4

    	

    

 

4.3 If the Company terminates
Executive’s employment for Cause as provided in Section 3.3 or if Executive terminates his employment pursuant to Section
3.1 (without Cause), then the Company’s sole obligation shall be to pay Executive amounts due or earned on the effective
termination date. Executive, except when employment terminates pursuant to Section 3.2(a) (death), shall continue to be subject
to Section 5 of this Agreement upon expiration or termination of this Agreement.

 

4.4 The Company’s obligation
to provide the payment and benefits under Section 4.2 is conditioned upon Executive’s execution of an enforceable release
of all claims (“Release”) and his compliance with the Non-Competition Agreement, as defined herein. If Executive chooses
not to execute the Release or fails to comply with the Non-Competition Agreement, then the Company’s obligation to compensate
him shall cease on the effective termination date except as to amounts due as of the date of termination. The Release shall be
provided to Executive within seven (7) days of his separation from service, and Executive must execute it within the time period
specified in the Release, which shall not be longer than forty-five (45) days from the date of receipt. Such Release shall not
be effective until any applicable revocation period has expired.

 

4.5 Executive is not entitled
to receive any compensation or benefits upon his termination except as set forth in this Agreement or otherwise required by any
employee benefit plan in which he participates. Moreover, the terms and conditions afforded Executive under this Agreement are
in lieu of any severance benefits to which he otherwise might be entitled pursuant to any severance plan, policy and practice of
the Company. Nothing in this Agreement, however, is intended to waive or supplant any death, disability, or other insurance or
retirement, 401(k) or pension benefits to which he may be entitled under employee benefit plans in which he participates.

 

5. NON-COMPETITION.
As part of the consideration for the compensation and benefits to be paid to Executive hereunder, including without limitation
the grant of stock options and as additional incentive for the Company to enter into this Agreement, Executive agrees to execute
prior to his commencement of employment and to abide by the Proprietary Information, Inventions, and Non-Competition Agreement
(the “Non-Competition Agreement”) attached hereto as Exhibit A.

 

6. EMPLOYEE REPRESENTATION.
Executive represents and warrants that to his knowledge his employment and obligations under this Agreement will not (a) breach
any duty or obligation he owes to another or (b) violate any law, recognized ethics standard or recognized business custom.

 

7. NOTICES.
All notices, requests, demands and other communications required or permitted to be given in writing pursuant to this Agreement
shall be deemed given and received: (a) upon delivery if delivered personally; (b) on the next day after being deposited with a
reliable overnight delivery service; or, (c) upon receipt of an answer back confirmation, if transmitted by email, addressed to
the below indicated e-mail address. Notice given in another manner shall be effective only if and when received by the addressee.
For purposes of notice, the addresses and email addresses of the parties shall be as follows:

 

    5

     

    

 

	If to the Executive, to :	Jeffrey H. Lawson. M.D., Ph.D. 
	 	[***]
	 	 
	If to the Company, to:	Paul A. Boyer, Chief Financial Officer
	 	Humacyte, Inc.
	 	P.O. Box 12695
	 	Durham, North Carolina 27709
	 	[***]

 

provided that: (a) each party shall have the right
to change its address for notice, and the person who is to receive notice, by the giving of fifteen (15) days’ prior written
notice to the other party in the manner set forth above; and (b) notices shall be effective if given to the other party in the
manner set forth above regardless of whether a copy was received by any additional addressee specified above.

 

8. WAIVER OF BREACH.
The Company’s or Executive’s waiver of any breach of a provision of this Agreement shall not waive any subsequent breach
by the other party.

 

9. SEVERABILITY.
If a court of competent jurisdiction holds that any provision or sub-part thereof contained in this Agreement is invalid, illegal
or unenforceable, that invalidity, illegality or unenforceability shall not affect any other provision in this Agreement.

 

10. PARTIES BOUND; ASSIGNMENT.
The terms, provisions, covenants and agreements contained in this Agreement shall apply to, be binding upon and inure to the benefit
of the Company’s successors and assigns. The Company, at its discretion, may assign this Agreement to its successors or affiliates.
Because this Agreement is personal to Executive, Executive may not assign this Agreement.

 

11. GOVERNING LAW.
This Agreement and the employment relationship created by it shall be governed by North Carolina law without giving effect to North
Carolina choice of law provisions. The parties hereby consent to jurisdiction in North Carolina for the purpose of any litigation
relating to this Agreement and agree that any litigation by or involving them relating to this Agreement shall be conducted in
the courts of Wake County, North Carolina, or the federal courts of the United States for the Eastern District of North Carolina.

 

12. SECTION 409A OF
THE INTERNAL REVENUE CODE

 

12.1 Parties’ Intent.
The parties intend that the provisions of this Agreement comply with Section 409A of the Internal Revenue Code of 1986, as amended
(the “Code”), and the regulations thereunder (collectively, “Section 409A”) and all provisions of this
Agreement shall be construed in a manner consistent with the requirements for avoiding taxes or penalties under Section 409A. If
any provision of this Agreement (or of any award of compensation, including equity compensation or benefits) would cause Executive
to incur any additional tax or interest under Section 409A, the Company shall, upon the specific request of Executive, use its
reasonable business efforts to in good faith reform such provision to comply with Section 409A; provided, that, to the maximum
extent practicable, the original intent and economic benefit to Executive and the Company of the applicable provision shall be
maintained, and the Company shall have no obligation to make any changes that could create any additional economic cost or loss
of benefit to the Company. The Company shall timely use its reasonable business efforts to amend any plan or program in which Executive
participates to bring it in compliance with Section 409A. Notwithstanding the foregoing, the Company shall have no liability with
regard to any failure to comply with Section 409A so long as it has acted in good faith with regard to compliance therewith.

 

    6

     

    

 

12.2 Separation from Service.
A termination of employment shall not be deemed to have occurred for purposes of any provision of this Agreement providing for
the payment of any amounts or benefits upon or following a termination of employment unless such termination also constitutes a
“Separation from Service” within the meaning of Section 409A and, for purposes of any such provision of this Agreement,
references to a “termination,” “termination of employment,” “separation from service” or like
terms shall mean Separation from Service.

 

12.3 Separate Payments.
Each installment payment required under this Agreement shall be considered a separate payment for purposes of Section 409A.

 

12.4 Delayed Distribution
to Specified Employees. If the Company determines in accordance with Section 409A and 416(i) of the Code and the regulations
promulgated thereunder, in the Company’s sole discretion, that the Executive is a specified employee of the Company, determined
in accordance with Section 409A, any payments and/or benefits provided under this Agreement that constitute “nonqualified
deferred compensation” subject to 409A that are provided to Executive on account of his Separation from Service shall not
be provided until the day after the six-month anniversary of Executive’s termination date (“Specified Employee Payment
Date”). The aggregate amount of any payments that would otherwise have been made to Executive during such six-month period
shall be paid in a lump sum to Executive on the Specified Employee Payment Date without interest and, thereafter, any remaining
payments and/or benefits shall be paid without delay in accordance with their original schedule.

 

13. ENTIRE AGREEMENT.
Except as expressly provided herein and except for the Non-Competition Agreement and existing and new Stock Option Agreements,
this Agreement: (a) supersedes all other understandings and agreements, oral or written, between the parties with respect
to the subject matter of this Agreement; and (b) constitutes the sole agreement between the parties with respect to the subject
matter hereof. Each party acknowledges that: (i) no representations, inducements, promises or agreements, oral or written, have
been made by any party or by anyone acting on behalf of any party, which are not embodied in this Agreement; and (ii) no agreement,
statement or promise not contained in this Agreement shall be valid. No change or modification of this Agreement shall be valid
or binding upon the parties unless such change or modification is in writing and is signed by the parties.

 

    	7

    	

    

 

IN WITNESS WHEREOF, the parties
have entered into this Agreement on the day and year first written above.

 

	 	EXECUTIVE
	 	 
	 	/s/ Jeffrey Lawson
	 	 
	 	HUMACYTE, INC.
	 	 
	 	/s/ Carrie S. Cox	 
	 	By:    Carrie S. Cox
	 	Title: Executive Chairman

 

    	8Exhibit 10.14.1

 

AMENDMENT 1 TO EXECUTIVE EMPLOYMENT
AGREEMENT (attached)

 

This Amendment 1 to the
Executive Employment Agreement (“Amendment”) is made and entered into by Humacyte, Inc. (“Humacyte” or
the “Company”) and Jeffrey Lawson, M.D. (hereinafter “Executive”) effective November 9, 2020.

 

WHEREAS, Executive has
served as the Company’s President and Chief Executive Officer pursuant to an Executive Employment Agreement dated June 19,
2018 (“the Employment Agreement”); and,

 

WHEREAS, the Company and
Executive wish to amend the Employment Agreement as stated in this Amendment 1.

 

NOW THEREFORE, in consideration
of the mutual promises set forth below and other good and valuable consideration, the receipt and sufficiency of which the parties
acknowledge, the Company and Executive agree as follows:

 

1. Employment
Agreement Section 1, Nature of Employment and Duties, is deleted in its entirety and replaced with the following:

 

1. NATURE
OF EMPLOYMENT AND DUTIES. Executive shall serve as Company’s Chief Surgical Officer and, as Vice-Chair to the Humacyte
Board of Directors, effective on the date first written above (the “Effective Date”) and have such responsibilities
and authority as the Company may lawfully assign from time to time. [Executive’s role as Vice Chair is subject to his election
to the Board of Directors of the Company by the Company’s stockholders.] Additionally, Executive agrees to perform such other
duties consistent with those of an executive at his level as the Company may lawfully direct from time to time. In his role as
Chief Surgical Officer, Executive shall report to the Company’s Chief Executive Officer.

 

1.1 Executive
shall perform all duties and exercise all authority in accordance with, and otherwise comply with, all lawful Company policies,
procedures, practices and directions.

 

1.2 Executive
shall devote all of his working time, reasonable best efforts, knowledge and experience to perform his duties and advance the
Company’s interests. Except as provided in 1.3 below regarding InnAVasc Medical, Inc. (“InnAVasc”), during
his employment, Executive shall not, directly or through others, engage in, assist or consult with any other business or
business activities of any nature whatsoever (including board memberships) without the Company’s prior written consent;
provided, however, this provision does not prohibit him from personally owning and trading in stocks, bonds, securities, real
estate, commodities or other investment properties for his own benefit which do not create actual or potential conflicts of
interest with the Company; nor does it prohibit him from serving on advisory boards, so long as such service does not violate
his obligations under the Non-Competition Agreement, as defined herein, or distract him from his duties under this Agreement.
Notwithstanding the foregoing, Executive shall continue to be permitted to serve as the President-Elect, President and Past
President of the Vascular Access Society of the Americas (“VASA”) and on the Executive
Advisory Board of the NIH Department of Defense funded Traumatic Injury study (“TACTIC”). Further, Executive may, if
he chooses to do so, take one (1) business day per month to conduct surgery at Duke University, and one (1) business day per month
to provide related clinical services to patients, provided that: Executive conducts all such activities solely in his personal
capacity and obtains customary malpractice and liability insurance for all such activities (it is understood that Humacyte will
not be responsible for such activities or such insurance); and, such surgery or clinical services do not interfere or conflict
with Executive’s duties to Humacyte. Such vacation days may be taken in addition to the vacation days to which Executive
is entitled under Section 2.2 of the Agreement.

 

    	 

    	

    

 

1.3 Humacyte
understands that Executive holds shares in InnAVasc. Executive may continue to hold and vote those shares and may transfer them
in whole or in part. He may also serve on the InnAVasc Board of Directors.

 

2. Employment
Agreement Section 5, Non-Competition, is deleted in its entirety and replaced with the following:

 

5. NON-COMPETITION.
As part of the consideration for the compensation and benefits to be paid to Executive hereunder, including without limitation
the amended terms in this Amendment 1, and as additional incentive for the Company to enter into this Amendment 1, Executive agrees
to execute and to abide by the Proprietary Information, Inventions, and Non-Competition Agreement (the “Non-Competition Agreement”)
attached to this Amendment 1 as Exhibit A.

 

3. Except
as modified in this Amendment 1, the Employment Agreement remains in full force and effect.

 

IN WITNESS WHEREOF, the
parties have entered into this Amendment 1 on the day and year first written above.

 

	 	EXECUTIVE
	 	 	 
	Feb. 2, 2021	/s/ Jeffrey Lawson 
	 	 	 
	 	HUMACYTE, INC.
	 	 	 
	 	/s/ Douglas Blankenship
	 	By:	Douglas Blankenship
	 	Title:	Chief Financial Officer

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00324-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00324-of-00352.parquet"}]]